



Cancer complexity (!?)


Søren M Bentzen, Ph.D., D.M.Sc.

Division of Biostatistics and Bioinformatics, UMGCC Shared Biostatistics Service
University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA

sbentzen@som.umaryland.edu

Complexity of human body

- A human body of 70 kg is comprised of:
 - $\sim 6.7 \cdot 10^{27}$ atoms and $\sim 10^{14}$ cells
- Activity:
 - $\sim 10^{25} - 10^{26}$ molecular reactions take place in human body
 - $\sim 10,000$ DNA single-strand breaks per cell per day
 - Blood and small intestine turnover per day: $\sim 10^{10} - 10^{11}$
- A human cell contains ~ 100 organelles and consists of:
 - $\sim 65\%$ water,
 - $\sim 1\%$ RNA and $\sim 1\%$ protein
- No. of genes in the human body: $\sim 20 - 25,000$




for more
information
on lung cancer,
keep smoking.

—— *the lung association british colombia*

CAUSES OF CANCER


• Genetic	5-10%
• Environmental	90-95%
• Tobacco	25-30%
• Diet & obesity	30-35%
• Infections	15-20%
• Radiation (ionizing & non-ionizing)	10%
• Pollution	?%

The hallmarks of cancer



Proliferation and hypoxia at the cellular level

Human HNSCC





blood vessels

proliferating cells
(IdUrd)


Hypoxia
(pimonidazole)

necrosis


What makes us unique?



Genes mirror geography



Single nucleotide polymorphisms



- Substitution of an alternate base pair at a specific nucleotide location
- Prevalence $\approx 1:300$ nucleotides
- Common SNPs in human genome
 - 7 million SNPs with MAF $> 5\%$
 - 4 million SNPs with $5\% > \text{MAF} > 1\%$

RADIOGENOMICS

Linking genomics to patient-to-patient variability in tumor or normal tissue response after radiation therapy alone or combined with drugs

Large studies in progress including 1,000+ patients each

SNP's & late RT toxicity: Validation study


UK RAPPER validation study

- 92 SNPs in 46 genes previously reported to be associated with RT toxicity
- 1613 patients: 976 post-op breast, 637 radical prostate RT
- Late toxicity assessed two years after RT
- After adjusting for multiple testing, study had 99% power to detect a SNP, with Minor Allele Frequency (MAF) of 0.35, associated with an odds ratio of 2.2.
- **NOT A SINGLE ONE OF THE 92 SNPs WAS SIGNIFICANT !!**

Int'l Radiogenomics Consortium

- 110 members from Europe, North America, Asia
- Steering Committee
 - *C West, B Rosenstein, J Alsner, SM Bentzen, J Chang-Claude, J Deasy, A Dunning, D Seminara, J Yarnold*
- Meetings: Manchester (2009), New York (2010), London (2011)
- Collected clinical outcome and genetic data on 5,603 patients from 20 published and unpublished studies
- Meta-analysis on associations between SNPs in TGFB1 and normal tissue toxicity in progress (*Barnett,...,Bentzen*)

Fibrosis vs. genotype



OR = 0.98 (95% CI 0.85, 1.11)
(99% CI 0.81, 1.16)

Incidence of G2+ fibrosis

Assuming a **25%** incidence with the common variant after adjustment for covariates... we can exclude an incidence of greater than **27.9%** for carriers of the rare allele of rs1800469 with >99% confidence

Genome wide association studies

Genome wide association studies (GWAS) take advantage of linkage disequilibrium, typically assessing 200,000–500,000 tag SNPs



Stage I
2,000 patients genotyped for 600,000 tagSNPs covering whole genome


Identify 5% most significant SNPs

Stage II
8,000 patients genotyped using a custom array containing SNPs identified in stage I


N = 10,000
P < 10⁻⁷

Barnett et al 2009, Nat Rev Cancer


Breast cancer subtypes





Genetic heterogeneity




Tumor heterogeneity




Genetic intra-tumor heterogeneity



Regional distribution of mutations




Phylogenetic relationship of tumor regions



Biomarker concordance primary v. met

Tumour type	Biomarker	Prognostic or predictive	Evidence of discordance
Oligodendroglioma	1p and 19q co-deletion <i>MGMT</i> promoter methylation	Prognostic/predictive Prognostic/predictive	Not applicable
Medullary thyroid	<i>RET</i> mutation	Prognostic ¹⁰²	Unknown
Breast	ER expression PR expression <i>HER2</i> amplification	Prognostic/predictive Prognostic Prognostic/predictive	7–25% 16–49% 3–24%
Lung	<i>EGFR</i> mutation <i>EML4-ALK</i> translocation	Prognostic/predictive Prognostic/predictive	0–38% 1–2%
Gastric	<i>HER2</i> amplification	Prognostic ¹⁰⁶ /predictive	1–3%
Colorectal	<i>KRAS</i> mutation	Predictive	0–10%
Melanoma	<i>BRAF</i> mutation	Prognostic/predictive	4–25%
Gastrointestinal stromal	<i>KIT</i> mutation <i>PDGFRA</i> mutation	Predictive Predictive	Acquired mutations evolve inhibitor treatment


Brain met volume versus time



Variance components



- Material: 247 independent brain mets in 86 evaluable patients from the WBRT alone arm of the phase III Metoxafin Gadolinium trial
- Endpoint: Relative tumor volume @ 4 months assessed from standardized Gd contrast MRI
- Maximum likelihood variance component analysis
- Variance components:
 - between subjects 57%
 - between lesions 43±5%

Levels of variance




Voxel-level correlation between tracers

Two canine patients with sino-nasal malignancy



The theragnostic imaging blind spot



Clinical trials and molecular profiling

